NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ELDN

Eledon Pharmaceuticals Inc

Jun 20 • 04:00PM ET

2.72

Dollar change -0.06
Percentage change -2.16	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB REGN AMGN GILD VRTX INCY ILMN ALNY BMRN NBIX

| Held by: VTI VXF IWC AVSC DFAC DFSU DFAS DCOR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.21	Insider Own	7.58%	Shs Outstand	59.88M	Perf Week	-9.33%
Market Cap	162.88M	Forward P/E	-	EPS next Y	-1.00	Insider Trans	0.00%	Shs Float	55.34M	Perf Month	-11.11%
Enterprise Value	38.88M	PEG	-	EPS next Q	-0.25	Inst Own	59.30%	Short Float	2.63%	Perf Quarter	-20.93%
Income	-41.59M	P/S	-	EPS this Y	-18.67%	Inst Trans	-0.02%	Short Ratio	6.91	Perf Half Y	-39.15%
Sales	0.00M	P/B	1.42	EPS next Y	-12.36%	ROA	-34.35%	Short Interest	1.46M	Perf YTD	-33.98%
Book/sh	1.91	P/C	1.30	EPS next 5Y	-14.98%	ROE	-83.30%	52W High	5.54 -50.90%	Perf Year	-3.55%
Cash/sh	2.09	P/FCF	-	EPS past 3/5Y	31.59% 50.24%	ROIC	-36.12%	52W Low	2.30 18.26%	Perf 3Y	-22.17%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	1.28% 2.53%	Perf 5Y	-70.66%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	83.36%	Oper. Margin	-	ATR (14)	0.18	Perf 10Y	-99.88%
Dividend Ex-Date	-	Quick Ratio	13.91	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	35.44	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	13.91	EPS Q/Q	89.31%	SMA20	-8.94%	Beta	-0.13	Target Price	9.00
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-10.36%	Rel Volume	1.14	Prev Close	2.78
Employees	31	LT Debt/Eq	0.00	Earnings	May 14 AMC	SMA200	-24.45%	Avg Volume	210.99K	Price	2.72
IPO	Sep 17, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	69.62% -	Trades		Volume	244,574	Change	-2.16%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-18-25	Resumed	H.C. Wainwright	Buy	$9
Jan-28-25	Initiated	Guggenheim	Buy	$9
May-13-22	Resumed	Cantor Fitzgerald	Overweight	$25 → $15
Mar-23-21	Initiated	Cantor Fitzgerald	Overweight	$25

May-23-25 12:00PM	What Makes Eledon Pharmaceuticals (ELDN) a New Buy Stock (Zacks)
May-14-25 04:01PM	Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results (GlobeNewswire)
May-03-25 08:15AM	Eledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance Sheet (Seeking Alpha)
Mar-27-25 10:16AM	Is Eledon Pharmaceuticals (ELDN) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-20-25 04:01PM	Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results (GlobeNewswire)
04:05PM	Loading…
Mar-04-25 04:05PM	Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-07-25 10:00AM	Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human (GlobeNewswire)
Jan-29-25 04:05PM	Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Jan-13-25 07:00AM	Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook (GlobeNewswire)
Nov-12-24 04:01PM	Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results (GlobeNewswire) -11.41%
Nov-06-24 04:05PM	Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference (GlobeNewswire)
Oct-29-24 07:46AM	Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +6.53%
07:45AM	Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine (GlobeNewswire)
Sep-11-24 04:05PM	Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-04-24 07:00AM	Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients (GlobeNewswire) -5.84%
05:21PM	Loading…
Aug-14-24 05:21PM	Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results (GlobeNewswire)
Jul-29-24 07:00AM	Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection (GlobeNewswire)
Jul-02-24 04:05PM	Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism (GlobeNewswire)
Jun-17-24 09:36AM	Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues (InvestorPlace) -6.93%
Jun-11-24 03:18PM	3 High-Potential Penny Stocks to Turn $1000 into $1 Million: June 2024 (InvestorPlace)
Jun-03-24 04:01PM	Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation (GlobeNewswire)
May-27-24 09:55AM	Eledon Pharmaceuticals (ELDN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
May-22-24 12:00PM	Eledon Pharmaceuticals, Inc. (ELDN) is a Great Momentum Stock: Should You Buy? (Zacks)
May-14-24 12:00PM	Eledon Pharmaceuticals (ELDN) Moves to Buy: Rationale Behind the Upgrade (Zacks) +6.85%
May-09-24 01:54PM	ELDN Stock Earnings: Eledon Pharma Beats EPS for Q1 2024 (InvestorPlace)
07:30AM	Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results (GlobeNewswire)
07:00AM	Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress (GlobeNewswire)
May-07-24 07:05AM	Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection (GlobeNewswire) -7.38%
07:00AM	Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement (GlobeNewswire)
Mar-28-24 04:01PM	Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results (GlobeNewswire)
04:56PM	Loading…
Mar-25-24 04:56PM	Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection (GlobeNewswire)
Mar-21-24 10:31AM	Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human (GlobeNewswire) +11.24%
Feb-13-24 07:01PM	Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-04-24 04:40PM	Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook (GlobeNewswire)
Dec-04-23 06:00PM	Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +16.67%
Nov-29-23 04:05PM	Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference (GlobeNewswire) -6.67%
Nov-09-23 04:01PM	Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results (GlobeNewswire)
Nov-08-23 04:05PM	Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Nov-02-23 09:05AM	Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation (GlobeNewswire) -10.37%
Oct-23-23 07:00AM	Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer (GlobeNewswire)
Oct-13-23 07:00AM	Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting (GlobeNewswire)
Oct-02-23 07:00AM	Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors (GlobeNewswire) +13.14%
Sep-25-23 07:00AM	Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human (GlobeNewswire)
Sep-20-23 04:05PM	Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-11-23 07:00AM	Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors (GlobeNewswire)
Sep-06-23 07:00AM	Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates (GlobeNewswire) -11.89%
Sep-05-23 07:00AM	Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation (GlobeNewswire)
Aug-16-23 07:00AM	Eledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation (GlobeNewswire)
Aug-10-23 07:00AM	Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results (GlobeNewswire)
Jul-12-23 07:30AM	Amerigo Reports Q2-2023 Production Results and Provides MVC Operational Update (GlobeNewswire)
Jun-02-23 08:00AM	Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-11-23 04:01PM	Eledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results (GlobeNewswire) -13.00%
May-04-23 04:05PM	Eledon Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 (GlobeNewswire) +6.33% +6.35%
May-01-23 07:00AM	Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials (GlobeNewswire) +9.52%
Apr-05-23 07:46PM	Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-31-23 06:00AM	Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology (GlobeNewswire) -5.98%
Mar-30-23 04:01PM	Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results (GlobeNewswire) +5.91%
Mar-23-23 04:05PM	Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023 (GlobeNewswire) -8.05%
08:00AM	Eledon to Present Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation at the World Congress of Nephrology 2023 (GlobeNewswire)
Feb-08-23 04:05PM	Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-09-23 08:31AM	Eledon Pharmaceuticals Provides Business and Pipeline Updates (GlobeNewswire)
08:30AM	eGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies (GlobeNewswire)
Dec-21-22 04:05PM	C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System (GlobeNewswire)
Nov-14-22 04:01PM	Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results (GlobeNewswire) +8.30%
Nov-03-22 04:05PM	Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022 (GlobeNewswire) -6.37%
Oct-24-22 04:05PM	Eledon Pharmaceuticals Announces Upcoming Presentations at ASNs Kidney Week 2022 and NEALS (GlobeNewswire)
Oct-03-22 08:00AM	Eledon Pharmaceuticals to Participate in Two Upcoming Conferences (GlobeNewswire)
Sep-22-22 04:05PM	Eledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference (GlobeNewswire) -7.93% -10.60%
Sep-06-22 04:01PM	Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy (GlobeNewswire)
Aug-29-22 08:00AM	Eledon Pharmaceuticals to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-11-22 04:01PM	Eledon Pharmaceuticals Reports Second Quarter 2022 Operating and Financial Results (GlobeNewswire)
Aug-04-22 04:05PM	Eledon Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022 (GlobeNewswire) +6.33%
Aug-01-22 05:00AM	Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients (GlobeNewswire)
Jul-18-22 08:00AM	Eledon Pharmaceuticals Announces the First Patient Dosed in Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation (GlobeNewswire)
Jun-10-22 04:05PM	Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +13.43% -8.03%
Jun-09-22 08:00AM	Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Pancreatic Islet Cell Transplantation (GlobeNewswire)
Jun-02-22 04:05PM	Eledon Pharmaceuticals to Present at the Jefferies Healthcare Conference (GlobeNewswire)
12:01PM	A number of insiders bought Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) stock last year, which is great news for shareholders (Simply Wall St.)
May-31-22 06:00AM	Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis (GlobeNewswire) -10.64%
May-12-22 04:01PM	Eledon Pharmaceuticals Reports First Quarter 2022 Operating and Financial Results (GlobeNewswire) +9.96%
May-09-22 08:00AM	Eledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy (GlobeNewswire) -12.01%
May-05-22 04:05PM	Eledon Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022 (GlobeNewswire) -5.44%
May-03-22 04:05PM	Eledon Pharmaceuticals to Participate in LifeSci Partners Immunology & Inflammation Symposium (GlobeNewswire)
Apr-18-22 04:05PM	Eledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference (GlobeNewswire) -8.25% +12.59%
Apr-14-22 04:05PM	Eledon to Host Virtual R&D Day on Thursday, April 28, 2022 (GlobeNewswire)
Mar-24-22 04:01PM	Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results (GlobeNewswire)
12:58PM	Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation (Simply Wall St.)
Mar-17-22 08:00AM	Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022 (GlobeNewswire)
Feb-14-22 08:00AM	Eledon Pharmaceuticals Provides Corporate Update and 2022 Outlook (GlobeNewswire)
Feb-08-22 04:05PM	Eledon Pharmaceuticals to Participate in 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire)
Jan-13-22 10:08AM	2 Strong Buy Penny Stocks That Could See Outsized Gains (TipRanks) +5.75%
Dec-27-21 05:17PM	Eledon Pharmaceuticals to Participate in January 2022 Investor Conferences (GlobeNewswire)
Dec-24-21 06:22AM	A number of insiders bought Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) stock last year, which is great news for shareholders (Simply Wall St.)
Nov-11-21 04:05PM	Eledon Pharmaceuticals Reports Third Quarter 2021 Operating and Financial Results (GlobeNewswire) +13.54%
Nov-04-21 05:34PM	Eledon Pharmaceuticals CEO David-Alexandre C. Gros, M.D., to Present at CareDx Virtual Transplant Innovation Day during ASN Kidney Week 2021 (GlobeNewswire)
04:05PM	Eledon Pharmaceuticals Announces Participation in November Conferences (GlobeNewswire)
Nov-01-21 08:00AM	Eledon Pharmaceuticals to Release Third Quarter Financial Results on Thursday, November 11, 2021 (GlobeNewswire)
Oct-19-21 07:00AM	CareDx and Eledon Pharmaceuticals Announce Collaborative Research Agreement (GlobeNewswire)
Oct-07-21 07:51AM	Eledon Pharmaceuticals Announces Presentation on AT-1501 at the Virtual 2021 Northeast Amyotrophic Lateral Sclerosis Consortium (GlobeNewswire)
Oct-05-21 04:22PM	Eledon Pharmaceuticals Announces Upcoming Presentation on AT-1501 at the Virtual 2021 International Pancreas and Islet Transplantation Association Congress (GlobeNewswire)

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm's compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. The company was founded on March 26, 2004 and is headquartered in Irvine, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ELDN

Eledon Pharmaceuticals Inc

Upgrade your FINVIZ experience